174 related articles for article (PubMed ID: 35676169)
1. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
Teo MY; Guercio BJ; Arora A; Hao X; Regazzi AM; Donahue T; Herr HW; Goh AC; Cha EK; Pietzak E; Donat SM; Dalbagni G; Bochner BH; Olgac S; Sarungbam J; Sirintrapun SJ; Chen YB; Gopalan A; Fine SW; Tickoo SK; Reuter VE; Weigelt B; Schultheis AM; Funt SA; Bajorin DF; Solit DB; Iyer G; Ostrovnaya I; Rosenberg JE; Al-Ahmadie H
Clin Genitourin Cancer; 2022 Oct; 20(5):431-441. PubMed ID: 35676169
[TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
3. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
[TBL] [Abstract][Full Text] [Related]
5. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
6. Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience.
Halabi IE; Husseini ZE; Haibe Y; Charafeddine M; Mukherji D; Temraz S; Bulbul M; Khauli R; Nasr R; Wazzan W; Hajj AE; Geara F; Shamseddine A
Cancer Treat Res Commun; 2020; 25():100222. PubMed ID: 33080450
[TBL] [Abstract][Full Text] [Related]
7. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS
Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of early stage small cell bladder cancer is not always dismal.
Lim JH; Sundar S
ESMO Open; 2019; 4(6):e000559. PubMed ID: 31798978
[TBL] [Abstract][Full Text] [Related]
11. Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome.
van de Kamp M; Meijer R; Pos F; Kerst M; van Werkhoven E; van Rhijn B; Horenblas S; Bex A
Urol Oncol; 2018 Jun; 36(6):307.e1-307.e8. PubMed ID: 29580697
[TBL] [Abstract][Full Text] [Related]
12. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder.
Rahman SN; Lokeshwar SD; Syed JS; Javier-Desloges JF; Press BH; Choksi AU; Rajwa P; Pradere B; Ploussard G; Kim JW; Monaghan TF; Renzulli JR; Shariat SF; Leapman MS
Urol Oncol; 2023 Feb; 41(2):107.e1-107.e8. PubMed ID: 36481253
[TBL] [Abstract][Full Text] [Related]
13. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
[TBL] [Abstract][Full Text] [Related]
14. Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.
Bazargani ST; Clifford TG; Djaladat H; Schuckman AK; Wayne K; Miranda G; Cai J; Sadeghi S; Dorff T; Quinn DI; Daneshmand S
Urol Oncol; 2019 Jan; 37(1):1-11. PubMed ID: 30470611
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
[TBL] [Abstract][Full Text] [Related]
16. Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.
Pasquier D; Barney B; Sundar S; Poortmans P; Villa S; Nasrallah H; Boujelbene N; Ghadjar P; Lassen-Ramshad Y; Senkus E; Oar A; Roelandts M; Amichetti M; Vees H; Zilli T; Ozsahin M
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):904-10. PubMed ID: 26104942
[TBL] [Abstract][Full Text] [Related]
17. Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials.
Gabrielson AT; Daniels MJ; Rowe J; Alam R; Lee EJ; Matoso A; De Felice A; Hahn N; Hoffman-Censits J; Bivalacqua TJ; Kates M
Urol Oncol; 2022 Apr; 40(4):164.e9-164.e16. PubMed ID: 35045949
[TBL] [Abstract][Full Text] [Related]
18. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE
Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
Sekar RR; Diamantopoulos LN; Bakaloudi DR; Khaki AR; Grivas P; Winters BR; Vakar-Lopez F; Tretiakova MS; Psutka SP; Holt SK; Gore JL; Lin DW; Schade GR; Hsieh AC; Lee JK; Yezefski T; Schweizer MT; Cheng HH; Yu EY; True LD; Montgomery RB; Wright JL
Clin Genitourin Cancer; 2023 Aug; 21(4):507.e1-507.e14. PubMed ID: 37150667
[TBL] [Abstract][Full Text] [Related]
20. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
